Medicinal herbal compounds for the prevention and treatment of diabetes

ABSTRACT

The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from  Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii  and  Anemarrhena asphodeloides.

FIELD OF THE INVENTION

The present invention is related to a medicinal herbal composition forpreventing or treating diabetes. The invention also relates to a methodof preventing or treating diabetes by administering the composition toan individual.

BACKGROUND OF THE INVENTION

Diabetes mellitus is a common, serious disease characterized byhyperglycemia. The disease can be divided into two major subclasses:insulin-dependent diabetes mellitus (IDDM), also known as type Idiabetes, and non-insulin-dependent diabetes mellitus (NIDDM), alsoknown as type II diabetes (World Health Organization Study Group.Diabetes mellitus. WHO Tech. Rep. Ser. 727:1-113, 1985). IDDM resultsfrom insulin deficiency caused by cell-mediated autoimmune destructionof pancreatic beta cells, and generally develops in the young (Yoon JW., Insulin-dependent diabetes mellitus. In: Roitt I M and Delves P J.(Eds.) Encyclopedia of Immunology, Second Edition. Academic Press Ltd.,London, pp. 1390-1398, 1998; Bach J F., Insulin-dependent diabetesmellitus as a beta cell targeted disease of immunoregulation. J.Autoimm. 8:439-463, 1995). IDDM accounts for approximately 10-15% of thediabetic population worldwide (World Health Organization Study Group.Diabetes mellitus. WHO Tech. Rep. Ser. 727:1-113, 1985). In contrast,NIDDM results from a variable combination of insulin resistance andinsulin deficiency, and generally develops in adults (Jun H S, et al.,Pathogenesis of non-insulin-dependent (Type II) diabetes mellitus(NIDDM)—Genetic predisposition and metabolic abnormalities. AdvancedDrug Delivery Reviews 35:157-177, 1999; DeFronzo R A., Thetriumvirate:—cell, muscle, liver: a collusion responsible for NIDDM.Diabetes 37:667-687, 1988). However, NIDDM can also develop at a youngerage, as seen in the maturity-onset diabetes of the young (Pirart J.,Diabetes mellitus and its degenerative complications: a prospectivestudy of 4400 patients observed between 1947 and 1973. Diabetes Care1:168-188, 1978). NIDDM accounts for over 85% of the diabetic populationworldwide. Both IDDM and NIDDM can cause microvascular and macrovascularcomplications, resulting in increases in morbidity and mortality (FajansS S, et al., Prediabetes, subclinical diabetes, and latent clinicaldiabetes: interpretation, diagnosis and treatment. In: Leibel D S,Wrenshall G S. (Eds.) On the Nature and Treatment of Diabetes. ExcerptaMedica, Amsterdam, pp. 641-656, 1965).

NIDDM is a complex disease that is currently thought to be influenced bymore than a single gene or environmental factor (Ghosh S, et al.,Genetic analysis of NIDDM. Diabetes 45:1-14, 1995; Kobberling J. Studieson the genetic heterogeneity of diabetes mellitus. Diabetologia 7:46-49,1971; Rotter J L, et al., Genetics of diabetes mellitus. In: Rifkin H,Porte D (Eds.) Diabetes Mellitus Theory and Practice. Elsevier, NewYork, pp. 378-413, 1990). Familial aggregation and the high concordancerate for the disease (60-100%) in identical twins suggest that geneticfactors play an important role in the pathogenesis of NIDDM (O'RahillyS, et al., Type 2 (noninsulin dependent) diabetes mellitus. New geneticsfor old nightmares. Diabetologia 31:407-414, 1988; Barnett A H, et al.,Diabetes in identical twins. A study of 200 pairs. Diabetologia20:87-93, 1981). In addition, environmental factors such as obesity,physical activity and diet also play a strong role in the development ofthe disease (Knowler W C, et al., Gm and type 2 diabetes mellitus: anassociation in American Indians with genetic admixture. Am. J. Hum.Genet. 43:520-526, 1988; Bennett P H, et al., Epidemiology and naturalhistory of NIDDM: non-obese and obese. In: Alberti K G M M, DeFronzo RA, Keen H, Zimmett P (Eds.) International Textbook of Diabetes Mellitus.Wiley, New York, pp. 147-176, 1992; Helmrich S P, et al., Physicalactivity and reduced occurrence of NIDDM. N. Engl. J. Med 325:147-152,1991). Although the relative contribution of genetic and environmentalfactors to the development of NIDDM differs among individuals, patientsgenerally have two common metabolic abnormalities, insulin resistanceand defects in glucose-stimulated insulin secretion, which lead to thedisease state (Saad M F, et al., A two step model for development ofnon-insulin-dependent diabetes. Am. J. Med. 90:229-235, 1991; DeFronzo RA, et al., Pathogenesis of NIDDM: A balanced overview. Diabetes Care15:318-368, 1992; Lillioja S, et al., Insulin resistance and insulinsecretory dysfunction as precursors of non-insulin-dependent diabetesmellitus. N. Engl. J. Med. 329:1988-1992, 1993).

The insensitivity of the target tissue in response to insulin (insulinresistance) appears to develop first in genetically predisposed subjectsin the presence of the necessary environmental factors (Jun H S, et al.,Pathogenesis of non-insulin-dependent (Type II) diabetes mellitus(NIDDM)—Genetic predisposition and metabolic abnormalities. AdvancedDrug Delivery Reviews 35:157-177, 1999). To compensate for this, thatis, to lower blood glucose and maintain normoglycemia, the secretion ofinsulin from the beta cells increases, resulting in hyperinsulinemia.Over time, the insulin resistance worsens, and the compensatory actionfails, leading eventually to impaired glucose tolerance. Insulinsecretion reaches a plateau, and beta cell function is impaired,resulting in insulin deficiency, and leading finally to hyperglycemicNIDDM. In addition, hyperglycemia itself leads to impaired insulinresistance and insulin secretion, exacerbating the disease.

The regulation of diet and exercise and/or treatment with insulin orhypoglycemia drugs have been used for the control of diabetes. Treatmentwith these agents is successful in some cases, but the mortality indexcontinues to rise. Insulin treatment provides symptomatic relief ratherthan a cure for NIDDM. Hypoglycemic agents such as sulfonylureas andbiguanides (metformin) also lower blood glucose, but again, simplyprovide symptomatic relief. Sulfonylureas lower the blood glucose levelby stimulating the release of insulin from pancreatic beta cells. Theseagents directly stimulate insulin release by closing adenosyltriphosphate (ATP)-sensitive potassium channels and depolarizing thecell membrane (Aguilar-Bryan L, et al., Cloning of the beta cellhigh-affinity sulfonylurea receptor: a regulator of insulin secretion.Science 268:423-426, 1995; Tan G H, et al., Pharmacologic treatmentoptions for non-insulin-dependent diabetes mellitus. Mayo ClinicProceedings 71:763-768, 1996; Lubbos H, et al., Oral hypoglycemic agentsin type II diabetes mellitus. American Family Physician. 52:2075-2078,1995) The side effects of sulfonylureas include hypoglycemia, renal andhepatic disease, gastrointestinal disturbances, increased cardiovascularmortality, dermatological reactions, dizziness, drowsiness and headache.Biguanides lower blood glucose levels by reducing intestinal glucoseabsorption and hepatic glucose, but not by stimulating insulinsecretion. The major side effects of biguanidine are lactic acidosis andincreased cardiovascular mortality. Alpha glucosidase inhibitors inhibitintestinal alpha glucosidases and consequently delay the digestion ofsucrose and complex carbohydrates. The side effects of alpha glucosidaseinhibitors include gastrointestinal side effects and hypoglycemia.Thiazolidinediones improve insulin resistance directly, enhancing theeffects of circulating insulin, directly stimulate peripheral glucoseuptake and inhibit glucose production in the liver. Thiazolidinedionesare only effective in the presence of insulin and may cause red bloodcell abnormalities, and headache.

Therefore, more effective drugs for the treatment of diabetes areclearly needed. We have long been interested in medicinal plants as apossible source for the development of hypoglycemic agents, and we havetried to halt the severe long-term complications of NIDDM in patientsusing extracts from various medicinal plants. We screened many plantsand found that certain combinations of plant extracts have hypoglycemiceffects. In particular, as exemplified infra, we discovered that thecombined extracts, designated medicinal herbal compounds for treatmentof type 2 diabetes (MHCTD), from Pterocarpus marsupium (Lodha R, et al.Traditional Indian systems of medicine. Ann. Acad. Med. Singapore29:37-41, 2000; Sheehan E W, et al., A constituent of Pterocarpusmarsupium, (−)-epicatechin, as a potential antidiabetic agent. J. Nat.Prod. 46:232-234, 1983; Manickam M, et al., Antihyperglycemic activityof phenolics from Pterocarpus marsupium. J. Nat. Prod. 60:609-610,1997), Morus alba (Chen F, et al., Hypoglycemic activity and mechanismsof extracts from mulberry leaves (folium mori) and cortex mori radicisin streptozotocin-induced diabetic mice. Yakugaku Zasshi 115:476-482,1995; Hikino H, et al., Isolation and hypoglycemic activity of moran A,a glycoprotein of Morus alba root barks. Planta Med. 2:159-160, 1985;Fukai T, et al., Structures of two natural hypotensive Diels-Alder typeadducts, mulberrofurans F and G, from the cultivated mulberry tree(Morus lhou KOIDZ.). Chem Pharm Bull (Tokyo). 33:3195-3204, 1985;Nikaido T, et al., Inhibition of adenosine 3′,5′-cyclic monophosphatephosphodiesterase by phenolic constituents of mulberry tree. Chem.Pharm. Bull. (Tokyo). 32:4929-4934, 1984), Orthosiphon aristatus (Hsu HY. Oriental Materia Medica: A Concise Guide. Oriental Healing ArtInstitute, Long Beach, Calif. p. 297), Opiophogon japonicus, Rosarugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhenaasphodeloides (Ichik H, et al., New antidiabetic compounds, mangiferinand its glucoside. Biol. Pharm. Bull 21:1389-1390, 1998; Miura T, etal., Antidiabetic effect of seishin-kanro-to in KK-Ay mice. Planta Med.63:320-322, 1997; Nakashima N, et al., Isolation ofpseudoprototimosaponin AIII from rhizomes of Anemarrhena asphodeloidesand its hypoglycemic activity in streptozotocin-induced diabetic mice.J. Nat. Prod. 56:345-350, 1993) showed a strong anti-diabetic effect inan animal model, the Goto-Kakizaki (GK) rat. In addition, treatment ofNIDDM patients with the combined extracts for 3 months to 1 yearsignificantly reduced blood glucose levels.

SUMMARY OF THE INVENTION

The present invention has met the hereinbefore described need.

An object of the invention is to provide a hypoglycemic effectivecomposition comprising extracts from Pterocarpus marsupium, Morus alba,Orthosiphon aristatus, Opiophogon japonicus, Anemarrhena asphodeloides,or Trichosanthis kirilowii, in combination with extracts from Rosarugosa and/or Commelina communis, and a pharmaceutically acceptablecarrier thereof.

The extracts may be present in a relative ratio to each other of:

about 3% by weight to about 90% by weight of Pterocarpus marsupium,

about 3% by weight to about 90% by weight of Morus alba,

about 3% by weight to about 90% by weight of Orthosiphon aristatus,

about 3% by weight to about 90% by weight of Opiophogon japonicus,

about 3% by weight to about 90% by weight of Rosa rugosa,

about 3% by weight to about 90% by weight of Commelina communis,

about 3% by weight to about 90% by weight of Trichosanthis kirilowii,and

about 3% by weight to about 90% by weight of Anemarrhena asphodeloides.

Preferably, the extracts may be present in a ratio of:

about 5% by weight to about 50% by weight of Pterocarpus marsupium,

about 5% by weight to about 50% by weight of Morus alba,

about 5% by weight to about 50% by weight of Orthosiphon aristatus,

about 5% by weight to about 50% by weight of Opiophogon japonicus,

about 3% by weight to about 50% by weight of Rosa rugosa,

about 3% by weight to about 50% by weight of Commelina communis,

about 3% by weight to about 50% by weight of Trichosanthis kirilowii,and

about 3% by weight to about 50% by weight of Anemarrhena asphodeloides.

Still more preferably, the extracts may be present in a ratio of:

about 20% by weight of Pterocarpus marsupium,

about 15% by weight of Morus alba,

about 20% by weight of Orthosiphon aristatus,

about 10% by weight of Opiophogon japonicus,

about 8% by weight of Rosa rugosa,

about 7% by weight of Commelina communis,

about 10% by weight of Trichosanthis kirilowii, and

about 10% by weight of Anemarrhena asphodeloides.

Another object of the invention is to provide the above composition,wherein the carrier is preferably a base of berries or fruit, a base ofvegetable soup or bouillon, a soya-milk drink, or a nutritivesupplement. In the case of using a base of berries or fruit, the basemay be preferably made of extracts from Rosa canina, Vaccinum myrtillusand/or Vaccinum vitis-idea. In the case where the base is made ofvegetable soup or bouillon, the base may be preferably made of extractsfrom Urtica diotica leaves, Allium cepa, and/or Ocimum sanctum.

The composition above may further include extracts from Arctium lapparoot, Eugenia jambolana seeds, Phaseus vulgaris husks, Trigonella foenumgraeam seeds, and Vaccinum myrtillus leaves. Preferably, the extractsmay be present in a ratio of:

about 5% by weight to about 20% by weight of Arctium lappa root,

about 5% by weight to about 70% by weight of Eugenia jambolana seeds,

about 5% by weight to about 20% by weight of Phaseus vulgaris husks,

about 10% by weight to about 30% by weight of Trigonella foenum graeamseeds, and

about 20% by weight to about 60% by weight of Vaccinum myrtillus leaves,wherein said ratio is relative to each of the extracts of Arctium lapparoot, Eugenia jambolana seeds, Phaseus vulgaris husks, Trigonella foenumgraeam seeds, and Vaccinum myrtillus leaves.

In another embodiment of the invention, the above composition mayfurther comprise chromium, manganese, zinc, niacin, vitamin B6 orvitamin B12. In such a composition, the chromium may be present in anamount of about 20 to about 500 micrograms, manganese may be present inan amount of about 1 to about 10 milligrams, zinc may be present in anamount of about 2 to about 10 milligrams, niacin may be present in anamount of about 50 to about 500 milligrams, vitamin B6 may be present inan amount of about 1 to about 50 milligrams, and vitamin B12 may bepresent in an amount of about 5 to about 100 micrograms per dose.

Any of the above compositions may further comprise extracts fromAcanthopanax, Schizandra, and optionally Rhodiola. Preferably, theextracts of Acanthopanax senticosus root, Schizandra chinensis fruit andseed, and Rhodiola rosea root are present in a ratio of about 4:2:1. Anexample of a Schizandra fixed combination is disclosed in HerbalMedicinal Product application nos. dnr 96-0045 and dnr 96-0046 beforethe Swedish Medical Product Agency, “the Swedish FDA”. The contents ofthese applications are incorporated by reference herein in theirentirety.

Another object of the invention is to provide a method of treating typeII diabetes comprising administering to a person in need thereof ananti-diabetic or hypoglycemic effective amount of any of the abovecompositions.

In yet another object of the invention, a method of preventing onset ofclinical type II diabetes is provided. The method comprisesadministering to a person in need thereof an anti-diabetic orhypoglycemic effective amount of any of the above compositions.

In still another object of the invention, a method of reducing bloodglucose levels in patients who have blood glucose levels of about 200 toabout 300 mg/dl at the beginning of treatment, is provided. The methodcomprises administering to the patient an effective amount of any of theabove compositions.

In other embodiments, a method of increasing insulin secretion frompancreatic β cells, comprising administering an effective amount of anyof the above compositions to a patient, is provided. A method ofinhibiting degradation of complex carbohydrates to monosaccharides,comprising administering any of the above compositions to a patient, isalso provided.

In another embodiment of the invention, this application provides for ahypoglycemic effective composition comprising extracts from Pterocarpusmarsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus,Anemarrhena asphodeloides, or a composition comprising extracts fromArctium lappa root, Eugenia jambolana seeds, Phaseus vulgaris husks,Trigonella foenum graeam seeds, and Vaccinum myrtillus leaves, incombination with extracts from Rosa rugosa and/or Commelina communis,and a pharmaceutically acceptable carrier thereof.

These and other objects of the invention will be more fully understoodfrom the following description of the invention, the referenced drawingsattached hereto and the claims appended hereto.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

The present invention will become more fully understood from thedetailed description given hereinbelow, and the accompanying drawingswhich are given by way of illustration only, and thus are not limitativeof the present invention, and wherein;

FIG. 1 shows the effect of MHCTD on insulin binding to its hepatocyteand muscle receptors. The insulin receptors were partially purified fromhepatocytes (A) or hindlimb skeletal muscle (B) of GK rats that weretreated with MHCTD or water for 5 months, and the rate of insulinbinding to these receptors was determined.

FIG. 2 shows the effect of MHCTD on insulin secretion from pancreaticbeta cells. GK rats that were treated with MHCTD or water for 5 monthswere anesthetized with phenobarbital. The pancreas was perfused withbuffer containing 16 mM glucose, the effluent was collected at 2 minintervals and the insulin secretion was measured.

FIG. 3 shows the effect of MHCTD on the degradation of carbohydratesinto monosaccharides. WF rats were treated with MHCTD or water for 2weeks and fasted overnight. The rats were then intubated with hydrolyzedstarch (2 g/kg) in water (2 g/20 ml) and blood glucose levels weredetermined 50 min after the intubation.

FIG. 4 shows the effect of MHCTD on the expression of glucosetransporters. The pancreatic islets were isolated from GK rats that weretreated with MHCTD or water. After the cell extracts were prepared,western blotting was performed with anti-Glut2 antibody and theexpression level of Glut2 was analyzed by densitometry and normalized bythe band intensity of GAPDH protein.

FIG. 5 shows the non-toxic effect of MHCTD on various organs. Normal WFrats were administered MHCTD at a dose 10 times higher than the regulardose (50 g/kg body weight) daily for 5 months beginning at 3 months ofage, and various organs were histologically examined. (A) Liver sectionshowing no sign of lymphocytic infiltration, necrosis or intranuclearglycogen infiltration; (B) kidney section showing intact glomeruli,tubules and vessels with no interstitial lymphocytic infiltration ornecrosis. (C) stomach section showing intact mucosa and no sign ofinflammatory cell infiltration or other cellular injury; (D) testessection showing no lesions and no cellular changes; (E) lung sectionshowing normal alveoli, bronchioles and bronchi; (F) brain sectionshowing intact nerve and glial cells in the cerebral cortex; (G) thymussection showing no observable lesions; (H) pancreatic section showing anintact morphology of both the endocrine islet and exocrine acinar cellswith no evidence of lymphocytic infiltration or necrosis; (I) thyroidsection showing no observable lesions; (J) adrenal section showing noobservable lesions; and (K) heart section showing normal endocardium andmyocardium.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a herbal medicinal composition thatcan be administered to a personal suffering from diabetes, preferablytype II diabetes, which results in the lowering of the blood glucoselevel of the patient. Administration of the composition to the patientboth prevented and treated incidences of clinical diabetes.

As used herein, “anti-diabetic” or “hypoglycemic” compound orcomposition generally refers to an agent that lowers blood glucoselevels. As a general guideline, without being limited to the valuessuggested herein, if blood glucose level is decreased by at least about100 mg/dl, then the compound is considered to be a hypoglycemic agent.For example, if the patient has a blood glucose level of 380 mg/dlbefore treatment, which decreases to 280 mg/dl after treatment, then thetreatment is considered to be a hypoglycemic agent. Such an agent or anyother agent that may lower blood glucose levels to other acceptedstandards of hypoglycemic effect, may be used to treat diabetes or toprevent the incidence of diabetes. The hypoglycemic or anti-diabeticeffect can be measured by a variety of methods including, but notlimited to, measuring the blood glucose levels, the rate of insulinbinding to its receptor, the level of insulin secretion from pancreaticbeta cells, and inhibition of glucohydrolase activity.

As used herein, “extract” refers to a concentrated preparation of theessential constituents of the medicinal plant. Typically, an extract isprepared by drying and powderizing the plant. Optionally, the plant, thedried plant or the powderized plant may be boiled in solution. Theextract may be used in liquid form, or it may be mixed with other liquidor solid medicinal herbal extracts. Alternatively, the medicinal herbalextract may be obtained by further precipitating solid extracts from theliquid form.

In further detail and/or alternatively, “extract” refers to aconcentrated preparation of the essential constituents of the medicinalplant. Typically, an extract is prepared by drying and subsequentlycutting or grinding the dried material. The extraction process may thenbe performed with the help of an appropriate choice of solvent,typically ethanol/water mixture, methanol, butanol, iso-butanol,acetone, hexane, petroleum ether or other organic solvents by means ofmaceration, percolation, repercolation, counter-current extraction,turbo-extraction, or by carbon-dioxide hypercritical(temperature/pressure) extraction. The extract may then be furtherevaporated and thus concentrated to yield a soft extract (extractumspissum) and/or eventually a dried extract, extracum siccum, by means ofspray drying, vacuum oven drying, fluid-bed drying or freeze-drying.

The herbal composition is made by drying and grinding various herbschosen from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus,Opiophogon japonicus, Anemarrhena asphodeloides, Trichosanthiskirilowii, Rosa rugosa, and Commelina communes. Most preferably, all ofthe herbs are used together in various ratios. But it is understood thatnot all of these herbs may be necessary for the desired effect ofreducing blood glucose levels in a patient. Any combination of theseherbs may be used so long as the composition lowers blood glucose levelsin the patient when administered to the patient.

In an embodiment of the invention, the herbal composition of theinvention may comprise any anti-diabetic, hypotensive plant extract thatis used in combination with Rosa rugosa, and/or Commelina communis.Preferably, the above-cited Pterocarpus marsupium, Morus alba,Orthosiphon aristatus, Opiophogon japonicus, Anemarrhena asphodeloides,Trichosanthis kirilowii plant extracts may be used in combination withRosa rugosa, and/or Commelina communis to form an anti-diabeticcomposition. Preferably, such a composition comprising Rosa rugosa,and/or Commelina communis will have a synergistic anti-diabeticactivity. Even more preferably, the anti-diabetic composition maycomprise all of the plant extracts of Pterocarpus marsupium, Morus alba,Orthosiphon aristatus, Opiophogon japonicus, Anemarrhena asphodeloides,Trichosanthis kirilowii, Rosa rugosa, and Commelina communis. Moreover,in this composition, Trichosanthis kirilowii may be substituted with acomposition comprising extracts from Arctium lappa root, Eugeniajambolana seeds, Phaseus vulgaris husks, Trigonella foenum graeam seeds,and Vaccinum myrtillus leaves.

The ratio of the extracts in the herbal composition may be the followingrelative to each other:

about 3% to about 90%, preferably about 5% to about 50%, even morepreferably about 6% to about 30%, and most preferably about 20% byweight of Pterocarpus marsupium,

about 3% to about 90%, preferably about 5% to about 50%, even morepreferably about 6% to about 30%, and most preferably about 15% byweight of Morus alba,

about 3% to about 90%, preferably about 5% to about 50%, even morepreferably about 6% to about 30%, and most preferably about 20% byweight of Orthosiphon aristatus,

about 3% to about 90%, preferably about 5% to about 50%, even morepreferably about 6% to about 30%, and most preferably about 10% byweight of Opiophogon japonicus,

about 3% to about 90%, preferably about 3% to about 50%, even morepreferably about 6% to about 20%, and most preferably about 8% by weightof Rosa rugosa,

about 3% to about 90%, preferably about 3% to about 50%, even morepreferably about 5% to about 20%, and most preferably about 7% by weightof Commelina communis,

about 3% to about 90%, preferably about 3% to about 50%, even morepreferably about 5% to about 20%, and most preferably about 10% byweight of Trichosanthis kirilowii, and

about 3% to about 90%, preferably about 3% to about 50%, even morepreferably about 5% to about 20%, and most preferably about 10% byweight of Anemarrhena asphodeloides.

In a preferred embodiment, a composition comprising extracts fromArctium lappa root, Eugenia jambolana seeds, Phaseus vulgaris husks,Trigonella foenum graeam seeds, and Vaccinum myrtillus leaves, maysubstitute for Trichosanthis kirilowii in any anti-diabetic herbalcombination in which an extract of Trichosanthis kirilowii is used.

Thus, according to one aspect, the invention relates to pharmaceuticalcompositions containing an anti-diabetic, hypoglycemic effective amountof the herbal compounds of the invention, mixed with suitablepharmaceutically acceptable excipients.

In an alternate embodiment of the invention, the herbal composition maycomprise extracts from the following plants: Arctium lappa root(Burdock), Eugenia jambolana seeds (Java plum, syn. Syzygium cuminii),Phaseus vulgaris husks (Bean husks), Trigonella foenum graeam seeds(Fenugreek seeds), and Vaccinum myrtillus leaves (Bilberry leaves).These plant extracts may be used individually or in combination, so longas anti-diabetic effect is maintained.

A ratio of these plant extracts may be the following relative to eachother:

about 5% to about 20%, preferably about 7% to about 15%, more preferablyabout 10% by weight of Arctium lappa root,

about 5% to about 70%, preferably about 7% to about 25%, more preferablyabout 20% by weight of Eugenia jambolana seeds,

about 5% to about 20%, preferably about 7% to about 15%, more preferablyabout 10% by weight of Phaseus vulgaris husks,

about 10% to about 30%, preferably about 15% to about 25%, morepreferably about 20% by weight of Trigonella foenum graeam seeds, and

about 20% to about 60%, preferably about 30% to about 50%, morepreferably about 40% by weight of Vaccinum myrtillus leaves.

In still another alternate embodiment of the invention, the medicinalherbal composition may comprise extracts of Acanthopanax senticosusroot, Schizandra chinensis fruit and seed, and/or Rhodiola rosea root.These plant extracts may be used individually or in combination, so longas anti-diabetic effect is maintained. A ratio of these plant extractsmay be about 4:2:1, respectively, relative to each other. Furthermore,at least Eleutherococcus B and E, Schizandrine, a-schizandrine,salidroside, and/or rosavine are active ingredients of these plantextracts.

In still another alternate embodiment, an active composition may be madefrom a mixture of chromium, manganese, zinc, niacin, vitamin B6 andvitamin B12. Preferably, the chromium is present in an amount of about20 to about 500 micrograms, manganese is present in an amount of about 1to about 10 milligrams, zinc is present in an amount of about 2 to about10 milligrams, niacin is present in an amount of about 50 to about 500milligrams, vitamin B6 is present in an amount of about 1 to about 50milligrams, and vitamin B12 is present in an amount of about 5 to about100 micrograms per dose.

As used herein, a “dose” refers to a specified quantity of a therapeuticagent prescribed to be taken at one time or at stated intervals.

It will be readily apparent that all of the above compositions in theiralternate forms may be used alone or in combination to provide ananti-diabetic herbal medicine, which when administered to a patient,results in diabetes preventive or therapeutic effect.

Depending on the specific clinical status of the disease, administrationcan be made via any accepted systemic delivery system, for example, viaoral route or parenteral route such as intravenous, intramuscular,subcutaneous or percutaneous route, or vaginal, ocular or nasal route,in solid, semi-solid or liquid dosage forms, such as for example,tablets, suppositories, pills, capsules, powders, solutions,suspensions, cream, gel, implant, patch, pessary, aerosols, collyrium,emulsions or the like, preferably in unit dosage forms suitable for easyadministration of fixed dosages. The pharmaceutical compositions willinclude a conventional carrier or vehicle and, in addition, may includeother medicinal agents, pharmaceutical agents, carriers, adjuvants, andso on. In the invention, the carrier for the herbal composition maypreferably include, a base of berries or fruit, a base of vegetable soupor bouillon, a soya-milk drink, or a nutritive supplement.

If a vegetable soup or bouillon base is desired to be used as a base forthe herbal composition, it can be readily seen that any vegetable soupor bouillon base can be used, so long as the anti-diabetic effect of theherbal composition is maintained. Preferably, the vegetable soup orbouillon may be made from extracts of Urtica diotica leaves, Alliumcepa, and/or Ocimum sanctum. However, it is understood that any of thesecomponents alone or in combination may be used as base for the inventivecomposition.

If it is desired that the base be made from extracts of berries orfruits, then it is understood that any berry or fruit base may be usedso long as its use does not interfere with the anti-diabeticeffectiveness of the herbal medicinal composition. Preferably, suchberries and fruits may comprise extracts from Rosa canina (dog rose),Vaccinum myrtillus (bilberry), and/or Vaccinum vitis-idea (ligonberry).However, it is understood that any of these components alone or incombination may be used as base for the inventive composition.

If the inventive composition is desired to be placed into a soya milk,it is understood that such a drink will need to be refrigerated toprevent toxic effects. It is further understood that the inventivecomposition may be placed, mixed, added to or combined with any othernutritional supplement so long as the anti-diabetic effect of the herbalcomposition is maintained.

If desired, the pharmaceutical composition to be administered may alsocontain minor amounts of non-toxic auxiliary substances such as wettingor emulsifying agents, pH buffering agents and the like, such as forexample, sodium acetate, sorbitan monolaurate, triethanolamine oleate,and so on.

The amount of the herbal medicine in a formulation can vary within thefull range employed by those skilled in the art, e.g., from about 0.01weight percent (wt %) to about 99.99 wt % of the medicine based on thetotal formulation and about 0.01 wt % to 99.99 wt % excipient.

The preferred mode of administration, for the conditions mentionedabove, is oral administration using a convenient daily dosage regimenwhich can be adjusted according to the degree of the complaint. For saidoral administration, a pharmaceutically acceptable, non-toxiccomposition is formed by the incorporation of the herbal composition inany of the currently used excipients, such as, for example,pharmaceutical grades of mannitol, lactose, starch, magnesium stearate,sodium saccharine, talc, cellulose, glucose, gelatin, sucrose, magnesiumcarbonate, and the like. Such compositions take the form of solutions,suspensions, tablets, pills, capsules, powders, sustained releaseformulations and the like. Such compositions may contain between 0.01 wt% and 99.99 wt % of the active compound according to this invention.

In one embodiment, the compositions will have the form of a sugar coatedpill or tablet and thus they will contain, along with the activeingredient, a diluent such as lactose, sucrose, dicalcium phosphate, andthe like; a disintegrant such as starch or derivatives thereof; alubricant such as magnesium stearate and the like; and a binder such asstarch, polyvinylpyrrolidone, acacia gum, gelatin, cellulose andderivatives thereof, and the like.

It is understood that by “pharmaceutical composition” or “herbalmedicinal composition”, it is meant that the herbal composition isformulated into a substance that is to be administered purposefully fortreating or preventing diabetes, preferably type II diabetes, in anindividual. The mode of action is believed to be by the reduction ofblood glucose levels. However, it is understood that the herbalcomposition per se will not have a toxic effect.

The invention is also directed to a method of treating type II diabetescomprising administering to a person in need thereof an effective amountof the composition described above.

Furthermore, in another embodiment of the invention, a method ofpreventing onset of clinical type II diabetes is disclosed, which methodcomprises administering to a person in need thereof an anti-diabetic,hypoglycemic effective amount of the composition described above.

In still another embodiment of the invention, a method of reducing bloodglucose levels in patients who have blood glucose level of about 200 toabout 300 mg/dl at the beginning of treatment is described, which methodcomprises administering to a patient an anti-diabetic, hypoglycemiceffective amount of the composition described above.

In another embodiment, the application discloses a method of increasinginsulin secretion from pancreatic β cells in a patient, comprisingadministering an effective amount of the herbal medicine compositiondescribed above to the patient.

In still another embodiment, the invention is directed to a method ofinhibiting degradation of complex carbohydrates to monosaccharides,comprising administering an effective amount of the above describedherbal composition to a patient.

The invention is described in further detail herein below.

NIDDM is a mild form of diabetes that often develops gradually duringmiddle age. However, later stages of this disease are very severe,resulting in long-term complications such as disease of the kidneys,heart, eyes, nerves and other organs. Unlike IDDM, diabetes does notdevelop from destruction of the pancreatic beta cells, but rather NIDDMdevelops by mechanisms such as insulin resistance, down-regulation ofinsulin receptors, defects in insulin secretion from the pancreatic betacells and other changes to the glucose transporter system. Although manyhypoglycemic agents including insulin, sulfonyl-urea and metformin havebeen used for the treatment of NIDDM, various side effects have beenobserved, and these agents give symptomatic relief rather than acting asa permanent treatment for NIDDM. Therefore, this investigation wasinitiated to develop anti-diabetic agents without significant sideeffects for the treatment of NIDDM using medicinal plant extracts.

We screened several medicinal plants and combinations of medicinalplants which are considered to improve the control of blood glucose, andfound that MHCTD showed a strong blood glucose lowering effect in GKrats, an NIDDM animal model.

We also treated 65 randomly selected NIDDM human patients that haddifferent initial ranges of blood glucose levels (200-600 mg/dl) withMHCTD for 3 to 6 months and found that MHCTD clearly lowered bloodglucose levels and prevented the long-term complications of diabetes.MHCTD treatment was generally more effective in patients who had a lowerblood glucose level in the beginning of treatment (200-300 mg/dl)compared to those who had a higher blood glucose level (400-600 mg/dl).In addition, the lowered blood glucose levels remained after 2 monthsafter termination of the MHCTD treatment. These results indicate thatMHCTD has an anti-diabetic effect in NIDDM patients.

Decreased insulin-stimulated glucose uptake is a characteristic ofinsulin resistance in NIDDM. The reduced number of insulin receptorsand/or reduced tyrosine kinase activity of the insulin receptor may bethe mechanisms involved in this insulin resistance. Thus, we examinedthe rate of insulin binding to its receptor in MHCTD-treated GK rats todetermine whether the enhancement of insulin receptor binding might bethe mechanism for the blood glucose level lowering effect on animal andhuman NIDDM. We found that the rate of insulin binding to insulinreceptors from both hepatocytes and smooth muscle was significantlyincreased in MHCTD-treated GK rats as compared with water-treated GKrats, indicating that MHCTD treatment can upregulate insulin receptors.

Glucose levels are maintained in normal subjects by a balance betweeninsulin secretion from pancreatic beta cells and insulin action in thesplanchnic (liver and gut) and peripheral (muscle and adipose) tissues.If this balance is broken by impaired beta cell function and/or abnormalinsulin action, then NIDDM develops. Therefore, the decrease of insulinsecretion from the pancreatic beta cells is one of the mechanismsinvolved in the development of NIDDM. To determine whether MHCTD has anyadvantageous effect on insulin secretion in pancreatic beta cells, weexamined the effect MHCTD on insulin secretion in GK rats. We found thatMHCTD treatment increased insulin secretion from the pancreatic betacells of GK rats. This result suggests that MHCTD contains a componentthat can enhance insulin secretion, resulting in a lower blood glucoselevel.

Complex carbohydrates in the diet are degraded into monosaccharides andabsorbed in the gastrointestinal tract. Since less biologically activeinsulin is produced in NIDDM patients, glucose is not utilized properly.Therefore, if the production of glucose from complex carbohydrates isinhibited, then a lower amount of insulin will be required to utilizeglucose. Alpha-glucohydrolase catalyzes the enzymatic degradation ofcomplex carbohydrates into monosaccharides (glucose). It is possiblethat MHCTD may inhibit alpha-glucohydrolase activity and decrease theblood glucose level. We measured blood glucose levels in normalMHCTD-treated WF rats after a starch feeding and found that the bloodglucose level was lower than that of water-treated, starch-fed WF rats.This may be due to the inhibition of the degradation of complexcarbohydrates to monosaccharides, suggesting that alpha-glucohydrolasemay be inhibited in MHCTD-treated WF rats, since both insulin secretionand insulin action are normal in WF rats.

In hyperglycemic animal models, the expression of Glut2 in thepancreatic beta cells was markedly decreased. It has been proposed thata loss of glucose-induced insulin secretion in NIDDM patients is causedby impaired glucose entry into beta cells. Therefore, we determinedwhether the level of Glut2 protein in pancreatic beta cells was changedin MHCTD-treated GK rats. We found that the expression of Glut2 proteinwas increased approximately two-fold compared with water-treated controlGK rats. This result suggests that MHCTD treatment may also increase theexpression of Glut2 to improve glucose uptake, subsequently increasingthe secretion of insulin and lowering blood glucose.

Type 2 diabetes is a complex disease that is influenced by genetic andenvironmental factors. The symptoms at the onset of the disease can bemild, but the severity of the disease gradually increases. Long-termdiabetics show increased risk for complications such as neuropathy,retinopathy, renopathy and infections. Therefore, appropriate treatmentin the early stages may result in the prevention of these long-termcomplications. So far, many hypoglycemic agents have been used for thecontrol of blood glucose levels. However, many of these agents havesignificant side effects. Therefore, efficient anti-diabetic agentswithout side effects are absolutely necessary for the control ofdiabetes as well as for the prevention of long-term complications. Ournewly developed medicinal herbal compound appears to be an idealanti-diabetic agent, since many of the diabetic patients who havereceived this compound report good control of blood glucose without anyappearance of side effects and the prevention of long-termcomplications. In addition, the treatment of a good number of patientswho had long-term complications with this medicinal herbal mixture(MHCTD) resulted in a great improvement or remission of the long-termcomplications.

The following examples are offered by way of illustration of the presentinvention, and not by way of limitation.

EXAMPLES Example 1 Materials And Methods—Extraction of Medicinal Plants

Pterocarpus marsupium was cultivated in India; the inside of the trunkwas harvested and dried. Morus alba was cultivated in Korea and northernChina; the leaves and roots were harvested and dried. Orthosiphonaristatus was cultivated in Vietnam; the whole plant, including roots,branches and leaves, was harvested and dried. Opiophogon japonicus, Rosarugose var typica (Regel) and Trichosanthis kirilowii (Maxim) andAnemarrhena asphodeloides (Bunge) were cultivated in Korea and northernChina; the roots were harvested and dried. Commelina communis (L.) wascultivated in Korea and China; the leaves, stems and flowers wereharvested and dried. Each dried component was powdered and mixed (P.marsupium (about 20%), O. aristatus (about 20%), M. alba (about 15%), O.japonicus (about 10%), T. kirilowii (about 10%), A. asphodeloides (about10%), R. rugosa (about 8%) and C. communis (about 7%) w/w. Forty gramsof the combined plant powder in 200 ml of water was boiled in a slowcooker until the volume was reduced to 100 ml. This mixture wasdesignated medicinal herbal compounds for treatment of type 2 diabetes(MHCTD).

Example 2 Goto-Kakizaki (GK) Rats

The GK rat (Goto Y, et al., Spontaneous diabetes produced by selectivebreeding of normal Wistar rats. Proc. Japan. Acad. 51:80-85, 1975;Sugiyama Y, et al., Role of hepatic insulin sensitivity in developmentof hyperglycemia of spontaneously diabetic GK rats. J. Japan. Diab. Soc.32:593-599, 1989) is one of the best animals for the study of NIDDM, asmost of these animals develop diabetes at about 3 months of age and thediabetic syndrome shares many pathological features with human NIDDM. GKrats show impaired insulin secretion and peripheral insulin resistance.Insulin response, sensitivity of glycogen synthesis, lipogenesis and DNAsynthesis in the hepatocytes of GK rats are markedly reduced as comparedwith non-diabetic control rats. In GK rats, the islet structure isdisrupted and areas of pronounced fibrosis are seen in the stroma. Asthe disease progresses, beta cell degranulation is observed, whilelymphocytic infiltration of the islets is not. Diabetic complicationssuch as neuropathy and nephropathy are found in these rats. We obtainedGK rats from Japan and used these animals to test the effect of MHCTD onhyperglycemia.

Example 3 Administration of MHCTD to GK Rats

To study the effect of MHCTD on the control of blood glucose in diabeticGK rats, 3 month-old rats were treated for 5 months with MHCTD preparedas described above. The animals were intubated daily (10:00 am) with 2.5ml (5 g/kg body weight). Age- and sex-matched GK rats were intubatedwith an equal volume of water as a control. Blood glucose levels weremeasured weekly using a One Touch glucometer until 1 year of age.

To study the effects of MHCTD on the prevention of diabetes, MHCTDtreatment of GK rats began at 3 weeks of age, prior to the onset ofNIDDM. Rats were intubated daily with MHCTD (5 g/kg body weight) orwater as described above until 13 weeks of age, and blood glucose levelswere measured weekly until 13 weeks of age.

Example 4 Analysis of the Expression of Insulin Receptors

Insulin receptors were purified from the hepatocytes and skeletal muscleof GK rats treated with MHCTD for 5 months beginning at 3 months of ageusing wheat germ agglutinin agarose (Klein H H, et al., Insulinactivation of insulin receptor tyrosine kinase in intact rat adipocytes.An in vitro system to measure histone kinase activity of insulinreceptors activated in vivo. J. Biol. Chem. 261:4691-4697, 1986; BurantC F, et al., Diabetes-induced functional and structural changes ininsulin receptors from rat skeletal muscle. J. Clin. Invest. 77:260-270,1986; Venkatesan N, et. at., Antidiabetic action of vanadyl in ratsindependent of in vivo insulin-receptor kinase activity. Diabetes40:492-498, 1991). The rate of insulin binding to solubilized receptorswas determined using [¹²⁵I]-labeled insulin. Briefly, the hepatocytes ormuscle tissue were homogenized in 4 volumes of 25 mM Hepes (pH 7.4), 5mM EDTA, 1 TIU/ml aprotinin, 2 mM phenylmethylsulfonyl fluoride (PMSF)and 1% Triton X-100. The homogenate was centrifuged at 10,000 g for 10min, and the supernatant was stirred at room temperature for 1 hr. Themixture was then centrifuged at 150,000 g for 90 min. The receptors werefurther purified by adsorption to and elution from agarose-bound WGA.Receptors were eluted from the WGA column with 25 mM Hepes (pH 7.4),0.1% Triton X-100 containing 0.3 M N-acetylglucosamine. The WGA eluate(50 microliters) was incubated with 10,000 cpm [¹²⁵I]-labeled insulin(specific activity: 125-175 microCi/micrograms) and with increasingconcentrations of unlabeled insulin for 16 hr at 4° C. in a buffercontaining 25 mM Hepes, 0.1% Triton X-100, 150 mM NaCl, 0.1% bovineserum albumin and 100 U/ml Bacitracin. The receptor and bound insulinwere precipitated by the addition of 100 microliters of 0.3% bovinegamma-globulin and 300 microliters of 25% polyethylene glycol andcollected by centrifugation. The resulting pellet was washed with 12%polyethylene glycol and counted in a Beckman Instruments gamma counter.The binding was related to the protein concentration in the WGA eluate.As a control, insulin receptors were purified from the GK rats treatedwith water.

Example 5 Analysis of Insulin Secretion in Pancreatic Beta Cells

GK rats treated with MHCTD or with water for 5 months beginning at 3months of age were anaesthetized with phenobarbital. The pancreas wasperfused as described previously (Portha B, et al., Beta-cellinsensitivity to glucose in the GK rat, a spontaneous nonobese model fortype II diabetes. Diabetes 40:486-491, 1991; Giroix M H, et a., Glucoseinsensitivity and amino-acid hypersensitivity of insulin release in ratswith non-insulin-dependent diabetes. A study with the perfused pancreas.Diabetes 32:445-451, 1983) using Krebs-Ringer bicarbonate buffer (118 mMNaCl, 4 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgSO₄, 1.2 mM KH₂PO₄, 25 mM NaHCO₃,1.2 g/L bovine serum albumin and 40 g/L dextran) containing 16 mMglucose. The effluent was collected from the cannula in the portal veinat 2 min intervals and stored at −20° C. Insulin secretion was measuredand calculated as described previously (Venkatesan N, et al.,Antidiabetic action of vanadyl in rats independent of in vivoinsulin-receptor kinase activity. Diabetes 40:492-498, 1991; Portha B,et al., Beta-cell insensitivity to glucose in the GK rat, a spontaneousnonobese model for type II diabetes. Diabetes 40:486-491, 1991).Briefly, plasma immunoreactive insulin was estimated using purified ratinsulin as a standard. The insulin secretion rate per total pancreas wascalculated using the flow rate and expressed as nM/min.

Example 6 Analysis of Alpha-glucohydrolase Reaction

We tested whether the degradation of complex carbohydrates intomonosaccharides by alpha-glucohydrolase-catalyzed enzymatic reactions isinhibited by treatment with the combined plant extracts. Wistar Furth(WF) rats treated with MHCTD (5 g/kg body weight) or water for 2 weekswere fasted overnight and intubated with heat-hydrolyzed starch (2 g/kg)suspended in water (2 g/20 ml). Blood samples were collected at 50 minafter intubation, and blood glucose levels were determined.

Example 7 Analysis of the Expression of Glucose Transporters

The expression level of glucose transporter 2 (Glut2) in the pancreaticbeta cells was determined by Western blot. GK rats treated with MHCTD orwater beginning at 3 months of age were sacrificed at 5 months aftertreatment. Pancreatic islet cell and muscle tissue extracts wereprepared and western blot was performed using anti-Glut2 and anti-Glut4antibodies (Santa Cruz Biotech. Inc., Santa Cruz, Calif.). The reactivebands were visualized using an enhanced chemoluminescence system(Amersham, Oakville, Ontario). The signal was analyzed by densitometricanalysis and normalized by the signal of anti-glyceraldehyde-3-phosphatedehydrogenase (GAPDH) antibody-reactive bands.

Example 8 Examination of Toxicity

Normal WF rats (n=40) were intubated with MHCTD (50 g/kg body weightwith extract that was concentrated 10×) daily for 5 months beginning at3 months of age. Each animal was sacrificed by CO₂ inhalation. Thestomach, testes, adrenal glands, thyroid gland, thymus, lung, heart,kidney, liver, brain and pancreas were removed, fixed with formalin andembedded in paraffin. The paraffin-embedded blocks were sectioned andstained with hematoxylin and eosin as described previously (Baek H S, etal., Direct involvement of macrophages in destruction of beta-cellsleading to development of diabetes in virus-infected mice. Diabetes40:1586-1597, 1991; Yoon J W, et al., Control of autoinmmune diabetes inNOD mice by GAD expression or suppression in beta cells. Science284:1183-1187, 1999).

Example 9 Treatment of NIDDM Patients with Combined Plant Extracts,MHCTD

To examine the effect of the combined plant extracts on NIDDM patients,40 g of the extracts combined in the proportions described in Example 1was mixed with 800 ml of water and slowly boiled for 6 to 12 hr untilthe volume was reduced by one-half. The supernatant was filtered toremove the precipitate and the filtered extract was divided into 4portions; each aliquot contained 100 ml of the combined plant extracts.The extract was administered orally to NIDDM patients 1 hour beforebreakfast, between meals and before sleep for 3 months to 1 year. Bloodglucose levels were measured before treatment began, after 3 months oftreatment and 2 months after termination of treatment.

Example 10 Results—Effect of Combined Plant Extracts (MHCTD) on BloodGlucose Level in GK Rats

To examine the effect of the combined plant extracts on the control ofblood glucose levels in GK rats, an animal model of NIDDM, GK rats weretreated with extract prepared as described in the Example 1. We foundthat GK rats treated daily with MHCTD for 5 months, commencing at 3months of age, showed a significantly decreased incidence of diabetes ascompared with water-treated control GK rats. After 3 months, theMHCTD-treated GK rats showed a decrease in disease incidence to 40% witha mean blood glucose level of 223 mg/dl. After 5 months of MHCTDtreatment, GK rats showed a decrease in disease incidence to 13%, whilethe water-treated control GK rats had a disease incidence of 93% (Table1). When we monitored blood glucose levels for a further 4 months aftertermination of MHCTD treatment, we found that the blood glucose levelswere within the normal range, although slightly increased (Table 2).

Example 11 Effect of MHCTD on the Prevention of Diabetes in GK Rats

To see whether the treatment of GK rats with MHCTD at an early age couldprevent the onset of clinical diabetes, we treated 3 week-oldpre-diabetic GK rats with MHCTD and examined blood glucose levels. Wefound that only 10% of the MHCTD-treated rats became diabetic by 9 or 13weeks of age, whereas 65% of the water-treated control rats werehyperglycemic at 9 weeks and 85% of the animals had become diabetic by11-13 weeks of age (Table 3).

Example 12 Effect of MHCTD on the Expression of Insulin Receptors

To determine the effect of MHCTD on the expression of insulin receptors,we measured the rate at which insulin binds to the receptors inMHCTD-treated GK rats. The rate of insulin binding to purified insulinreceptors from hepatocytes and muscle cells was significantly increasedin MHCTD-treated GK rats compared with water-treated controls (FIGS. 1A,1B). These results indicate that MHCTD may enhance the expression ofinsulin receptors.

Example 13 Effect of MHCTD on Insulin Secretion in Pancreatic Beta Cells

To see whether MHCTD has any effect on insulin secretion from pancreaticbeta cells, the insulin level in the blood was measured. We found thatthe secretion of insulin from MHCTD-treated GK rats was clearlyincreased compared to water-treated control GK rats (FIG. 2). Thisresult suggests that MHCTD may enhance the secretion of insulin frompancreatic beta cells, probably as a result of an increase in insulinsynthesis.

Example 14 Effect of MHCTD on the Inhibition of Alpha-glucohydrolase

Carbohydrates in the diet must be degraded to monosaccharides byalpha-glucohydrolase in order to be absorbed in the gastrointestinaltract. In NIDDM patients there is less biologically active insulin tofacilitate uptake of glucose. Therefore, the inhibition of complexcarbohydrate degradation into monosaccharides may reduce the amount ofabsorbable glucose, resulting in a reduced requirement for insulin. Todetermine whether MHCTD treatment inhibits the degradation of complexcarbohydrates into monosaccharides by the inhibition ofalpha-glucohydrolase, we administered MHCTD and starch, water andstarch, or water alone into WF rats and blood glucose levels weremeasured. We found that the blood glucose levels of WF rats thatreceived MHCTD and starch were lower than that of WF rats administeredwater and starch but higher than that of WF rats administered waterwithout starch (FIG. 3). As both insulin secretion and insulin actionare normal in WF rats, these results suggest that the lower bloodglucose levels in MHCTD-treated rats may result from a reduceddegradation of complex carbohydrates.

Example 15 Effect of MHCTD on the Glucose Transporter

Glucose enters the beta cells through a membrane-bound facilitatedtransporter, Glut2. It has been suggested that impaired glucose entryinto beta cells results in decreased glucose-induced insulin secretionin NIDDM patients. In animal models, it was reported that the expressionof Glut2 protein is markedly decreased in the beta cells. Therefore, wedetermined the level of Glut2 protein in the pancreatic beta cell bywestern blotting, and found that the expression of Glut2 protein wassignificantly increased (about 2-fold) in the pancreatic beta cells ofMHCTD-treated GK rats compared to water-treated GK rats (FIG. 4).

Example 16 Toxic Effect of MHCTD on Various Organs

Normal WF rats were administered MHCTD at a dose 10 times higher thanthe regular dose (50 g/kg body weight) daily for 5 months beginning at 3months of age. At the end of the treatment, the animals were sacrificedand major organs including the stomach, testes, adrenal glands, thyroidgland, thymus, lung, heart, kidney, liver, brain and pancreas wereremoved. Sections of each organ were stained with hematoxylin and eosinand examined under the light microscope. Sections of stomach showedintact mucosa and no sign of inflammatory cell infiltration or othercellular injury. Lung sections showed normal appearing alveoli,bronchioles, bronchi and vessels. Heart sections showed normalendocardium and myocardium. Kidney sections showed intact glomeruli,tubules and vessels. There was no interstitial lymphocytic infiltrationor necrosis. The lobules of the liver were well defined and the cords ofhepatocytes were clearly separated by anastomosing sinuses and thecentral vein. There was no sign on lymphocytic infiltration, necrosis orintranuclear glycogen infiltration. Brain sections showed intact nerveand glial cells in the cerebral cortex. There was no evidence ofnecrosis, hemorrhage or infarction. Pancreatic sections showed an intactmorphology of both the endocrine islet and exocrine acinar cells. Therewas no evidence of lymphocytic infiltration or necrosis. These resultsindicate that treatment with a high dose of MHCTD does not result indeleterious effects on the major organs examined (FIG. 5).

Example 17 Effect of MHCTD on the Control of Blood Glucose in NIDDMPatients

To determine whether MHCTD can control blood glucose in patients withNIDDM, randomly selected volunteers who had been diabetic for 3-7 yearswere treated with MHCTD. We found that all of these patients showed asignificant decrease in blood glucose (Table 4). Three (YWB, KSW, OSW)of these 9 patients that had blood glucose levels close to 400 mg/dl(382-398 mg/dl) before treatment showed blood glucose levels around 140mg/dl (114-162 mg/dl) after treatment. In addition, 4 other patients(LTW, JKS, YCS, PKH) who had blood glucose levels from 412-462 mg/dlbefore treatment showed blood glucose levels of around 160 mg/dl(121-184 mg/dl) after treatment. The two patients who had blood glucoselevels from 476-510 mg/dl (SBS, CSS) before treatment showed bloodglucose levels of around 200 mg/dl (194-214 mg/dl) after treatment. Thisresult indicates that treatment of diabetic patients with MHCTD resultsin the significant decrease of blood glucose levels in all the patientstested.

To determine whether the termination of MHCTD treatment would reversethe level of blood glucose, we stopped MHCTD treatment of the patientsfor two months and then measured blood glucose levels. We found thatthere was no significant change in blood glucose in all the diabeticpatients tested (Table 4).

We also tested 65 additional diabetic patients. These patients weredivided into 4 groups on the basis of blood glucose levels before MHCTDtreatment: group A—blood glucose levels between 200-300 mg/dl, groupB—blood glucose levels between 301-400 mg/dl, group C—blood glucoselevels between 401-500 mg/dl and group D—blood glucose levels between501-600 mg/dl. In group A, about 65% ({fraction (15/23)}) of theMHCTD-treated patients showed a reduction of blood glucose (below 150mg/dl), about 13% ({fraction (3/23)}) showed a reduction in their bloodglucose level below 200 mg/dl, and there was no significant change(201-300 mg/dl) in the rest of the patients (22%; {fraction (5/23)}). Ingroup B, 43% ({fraction (12/28)}) of the MHCTD-treated patients showed adecrease in blood glucose levels below 150 mg/dl, 32% ({fraction(9/28)}) showed blood glucose levels between 151-200 mg/dl, 14%({fraction (4/28)}) showed blood glucose levels between 201-300 mg/dl,and 11% ({fraction (3/28)}) showed no significant change in bloodglucose levels (301-400 mg/dl). In group C, about 17% ({fraction(2/12)}) of the MHCTD-treated patients showed a decrease in their bloodglucose levels below 150 mg/dl, 67% ({fraction (8/12)}) showed bloodglucose levels between 151-200 mg/dl, and 17% ({fraction (2/12)}) showedno significant change in blood glucose levels (250-500 mg/dl). In groupD patients, one out of two patients treated with MHCTD showed a bloodglucose level below 150 mg/dl, and the other showed a blood glucoselevel of 291 mg/dl (Table 5).

All of the references cited herein are incorporated by reference hereinin their entirety.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention specifically described herein. Suchequivalents are intended to be encompassed in the scope of the followingclaims.

TABLE 1 Effect of MHCTD on blood glucose level in GK rats¹ Duration ofMean blood glucose Incidence of Treatment treatment (months) (mg/dl ±SD) diabetes (%) MHCTD 0 392 ± 28 90 (27/30) 1 321 ± 29 77 (23/30) 2 268± 35 60 (18/30) 3 223 ± 38 40 (12/30) 4 183 ± 39 27 (8/30)  5 143 ± 4313 (4/30)  Water 0 381 ± 25 90 (27/30) 1 386 ± 27 90 (27/30) 2 392 ± 1990 (27/30) 3 395 ± 17 93 (28/30) 4 389 ± 21 93 (28/30) 5 393 ± 17 93(28/30) ¹GK rats at 3 months of age were intubated with MHCTD or water.The mean non-fasting blood glucose levels of normal non-diabetic WF ratsis 143 ± 19 mg/dl. Any GK rats that had a blood glucose level of 5 SDabove this mean ( over 238 mg/dl) were considered diabetic (n =30/group).

TABLE 2 Effect of MHCTD on blood glucose levels in GK rats aftertermination of treatment.¹ Months after Incidence termination of Meanblood glucose of diabetes treatment (mg/dl ± SD) (%) 0 143 ± 43 13(4/30) 1 152 ± 38 17 (5/30) 2 160 ± 39 17 (5/30) 3 171 ± 42 20 (6/30) 4174 ± 47 20 (6/30) ¹GK rats were treated with MHCTD for 5 months asdescribed in Example 10. Blood glucose levels were monitored for 4months after termination of the treatment.

TABLE 3 Effect of MHCTD on the prevention of NIDDM in GK rats.¹ Age ofanimal Mean blood glucose Incidence of diabetes Treatment (weeks) (mg/dl± SD⁺ (%) MHCTD 3 145 ± 29  0 (0/20) 5 152 ± 31  0 (0/20) 7 163 ± 35  5(1/20) 9 172 ± 42 10 (2/20) 11 168 ± 39 10 (2/20) 13 171 ± 40 10 (2/20)Water 3 147 ± 33  0 (0/20) 5 172 ± 28  0 (0/20) 7 218 ± 45 20 (4/20) 9320 ± 51  65 (13/20) 11 368 ± 39  85 (17/20) 13 376 ± 31  85 (17/20) ¹GKrats were treated with MHCTD or water from 3 weeks of age for 2 months,and blood glucose levels were determined weekly.

TABLE 4 Effect of MHCTD on the control of blood glucose in NIDDMpatients. Dura- Blood glucose tion Blood glucose level after Bloodglucose level of level before 3 months of 2 months after diabetestreatment treatment termination of Patient (years) (mg/dl) (mg/dl)treatment (mg/dl) YWB 3 382 126 139 KSW 3 396 162 174 OSW 3 398 114 128LTW 4 412 184 198 JKS 5 424 148 176 YCS 3 426 121 146 PKH 5 462 126 131SBS 6 476 214 248 CSS 7 510 194 216 ¹NIDDM patients were treated withMHCTD as described in Example 17 for 3 months, and blood glucose levelswere determined. Blood glucose levels were measured again 2 months aftertermination of the treatment. Patients who had been diabetic for 3 yearsdid not receive any other medication at the time of treatment. Patientswho had been diabetic for 4-5 years took sulfonylurea for 1 month aftercommencement of MHCTD treatment, #and then terminated the treatment.Patients who had been diabetic 6-7 years took sulfonylurea for 2 monthsafter commencement of MHCTD treatment, and then terminated thetreatment.

TABLE 5 Effect of MHCTD on the control of blood glucose in 65 NIDDMpatients.¹ Before Treatment After treatment Blood glucose Number ofBlood glucose level Number of Group level (mg/dl) patients (mg/dl)patients A 200-300 23 101-150 15 151-200 3 201-250 3 252-300 2 B 301-40028 101-150 12 151-200 9 201-250 1 251-300 3 301-350 1 351-400 2 C401-500 12 101-150 2 151-200 8 250-500 2 D 501-600 2 101-150 1 251-300 1¹Sixty-five randomly selected NIDDM patients were treated with MHCTD for3-6 months. Patients with blood glucose levels of 200-300 mg/dl did notreceive any medication. Patients with blood glucose levels of 301-400mg/dl, and took sulfonyl urea for only 1 month after commencement ofMHCTD treatment. Patients with blood glucose levels of 401-500 mg/dltook sulfonylurea for only 2 months after commencement of MHCTDtreatment. Patients #with blood glucose levels of 501-600 mg/dl tooksulfonylurea and received insulin injections for only 2 months aftercommencement of MHCTD treatment. Blood glucose levels were measured onehour after meals.

What is claimed is:
 1. A hypoglycemic effective composition comprisingextracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus,Opiophogon japonicus, Anemarrhena asphodeloides, or Trichosanthiskirilowii, in combination with extracts from Rosa rugosa and/orCommelina communis, and a pharmaceutically acceptable carrier thereof,wherein said extracts are present in a ratio of: about 20% by weight ofPterocarpus marsupium, about 15% by weight of Morus alba, about 20% byweight of Orthosiphon aristatus, about 10% by weight of Opiophogonjaponicus, about 8% by weight of Rosa rugosa, about 7% by weight ofCommelina communis, about 10% by weight of Trichosanthis kirilowii, andabout 10% by weight of Anemarrhena asphodeloides.
 2. The compositionaccording to claim 1, wherein said carrier is a base of berries orfruit, a base of vegetable soup or bouillon, a soya-milk drink, or anutritive supplement.
 3. The composition according to claim 2, whereinsaid base of berries or fruit comprises extracts from Rosa canina,Vaccinum myrtillus or Vaccinum vitis-idea.
 4. The composition accordingto claim 2, wherein said base of vegetable soup or bouillon comprisesextracts from Urtica diotica leaves, Allium cepa, or Ocimum sanctum. 5.The composition according to claim 1, which further comprises extractsfrom Arctium lappa root, Eugenia jambolana seeds, Phaseus vulgarishusks, Trigonella foenum graeam seeds, or Vaccinum myrtillus leaves. 6.The composition according to claim 1, which further comprises chromium,manganese, zinc, niacin, vitamin B6 or vitamin B12.
 7. The compositionaccording to claim 6, wherein said chromium is present in an amount ofabout 20 to about 500 micrograms, manganese is present in an amount ofabout 1 to about 10 milligrams, zinc is present in an amount of about 2to about 10 milligrams, niacin is present in an amount of about 50 toabout 500 milligrams, vitamin B6 is present in an amount of about 1 toabout 50 milligrams, or vitamin B12 is present in an amount of about 5to about 100 micrograms per dose.
 8. The composition according to claim1, which further comprises extracts from Acanthopanax, Schizandra, andoptionally Rhodiola.
 9. The composition according to claim 5, whichfurther comprises chromium, manganese, zinc, niacin, vitamin B6 orvitamin B12.
 10. The composition according to claim 5, which furthercomprises extracts from Acanthopanax, Schizandra, and optionallyRhodiola.
 11. The composition according to claim 6, which furthercomprises extracts from Acanthopanax, Schizandra, and optionallyRhodiola.
 12. The composition according to claim 9, which furthercomprises extracts from Acanthopanax, Schizandra, and optionallyRhodiola.
 13. The composition according to claim 8, wherein the extractsof Acanthopanax senticosus root, Schizandra chinensis fruit and seed,and Rhodiola rosea root are present in a ratio of about 4:2:1.
 14. Amethod of treating type II diabetes comprising administering to a personin need thereof a hypoglycemic effective amount of the compositionaccording to claim
 1. 15. A method of reducing blood glucose level in apatient who has blood glucose level of about 200 to about 300 mg/dl atthe beginning of treatment, comprising administering to said patient ahypoglycemic effective amount of the composition according to claim 1.16. A method of increasing insulin secretion from pancreatic β cells,comprising administering an effective amount of the compositionaccording to claim 1 to an individual.
 17. A method of inhibitingdegradation of complex carbohydrates to monosaccharides, comprisingadministering the composition according to claim 1 to an individual.